Regen Lab

Executive Summary

Regen Lab SA is a Swiss medical device company founded in 2003, specializing in autologous cell therapies and regenerative medicine. The company is a global leader in bedside systems for preparing platelet-rich plasma (PRP), hyaluronic acid combinations, and extracellular matrices. Its products are used in aesthetics, orthopaedics, and general medical care, leveraging the body's own healing mechanisms. With over two decades of experience, Regen Lab has established a strong presence in the regenerative medicine market, offering innovative solutions that enable point-of-care treatments. The company's focus on autologous therapies positions it well in the growing trend toward personalized, minimally invasive procedures. While private, Regen Lab continues to expand its product portfolio and geographic reach, driven by clinical evidence and physician adoption. The company's commitment to quality and innovation supports its reputation as a key player in the regenerative medicine space.

Upcoming Catalysts (preview)

• TBDPotential FDA clearance for new PRP or HA combination product in the US market60% success
• TBDExpansion into emerging markets through regulatory approvals or distribution partnerships70% success
• TBDPublication of clinical study data supporting product efficacy in orthopaedics or aesthetics80% success